7 assets in Luminal B Breast Carcinoma

Therapeutic assets addressing Luminal B Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ribociclib Luminal B Breast Carcinoma	Danish Breast Cancer Cooperative Group	P3	BB (66)
Durvalumab Luminal B Breast Carcinoma	Jules Bordet Institute	P2	B (63)
Abemaciclib Luminal B Breast Carcinoma	Danish Breast Cancer Cooperative Group	P3	B (60)
Trastuzumab Deruxtecan Luminal B Breast Carcinoma	Danish Breast Cancer Cooperative Group	P3	B (60)
Goserelin Luminal B Breast Carcinoma	University Hospital, Akershus	P2	B (57)
Letrozole Luminal B Breast Carcinoma	University Hospital, Akershus	P2	B (57)
Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer Luminal B Breast Carcinoma	Jules Bordet Institute	P2	CCC (53)